Two consecutive 20cm limit increases have attracted regulatory attention.
On December 23, Aba Chemicals Corporation(300261) received a letter of concern, and Shenzhen Stock Exchange asked it to explain whether the company indirectly provided carlon anhydride products to Pfizer; Whether there is any violation of the principle of fairness of information disclosure or misleading investors, and whether there is any use of information disclosure to hype stock prices.
Aba Chemicals Corporation(300261) realize the 20% limit again
clarification: there is no direct cooperative relationship with Pfizer
On December 23, Aba Chemicals Corporation(300261) quickly raised the closing limit after the opening and realized the 20cm limit again. In the past four trading days, the stock has increased by 74.5%. As of the closing, the stock was reported at RMB 12.88, with a total market value of RMB 12.4 billion.
After hours, Aba Chemicals Corporation(300261) issued a prompt announcement on abnormal fluctuations in stock trading again. Aba Chemicals Corporation(300261) said that the company’s share price has increased greatly in the short term, but the production and operation situation has not changed significantly, and there may be a risk of speculation in the secondary market.
In view of the abnormal fluctuation of the company’s stock, Aba Chemicals Corporation(300261) re emphasized that the company did not directly sign any cooperation agreement with Pfizer, had no direct cooperation relationship with Pfizer, and did not directly supply carlon anhydride products to Pfizer. The sales revenue of the company’s carbonic anhydride products accounts for a small proportion of the company’s annual total operating revenue, which will not have a significant impact on the company’s performance. A2w Pharma Ltd, a subsidiary of the company in Malta. The main structure of CBD (cannabinoid) product production workshop has been basically completed and has not been officially put into operation.
Through self-examination, the company does not violate the fair disclosure of information. There is no need to correct or supplement the information disclosed by the company in the early stage. The company, its controlling shareholders and actual controllers do not have any major events that should be disclosed but not disclosed, nor do they have any major events in the planning stage. During the period of stock change, the controlling shareholder and actual controller of the company do not buy or sell the company’s shares. The company reminds investors to pay attention to the transaction risks in the secondary market, make rational decisions and invest prudently.
Aba Chemicals Corporation(300261) received the attention letter of Shenzhen Stock Exchange
is there a case of using the letter Phi to hype the stock price
Nevertheless, the continuous surge of Aba Chemicals Corporation(300261) has attracted regulatory attention. On December 23, Shenzhen Stock Exchange issued a concern letter to Aba Chemicals Corporation(300261) .
The supervision letter pointed out that from November 1 to December 23, 2021, Aba Chemicals Corporation(300261) share price rose by 151.07% in total, which was more deviated from the gem composite index in the same period. During the period, it touched the abnormal fluctuation of stock trading on December 22, and the company’s share price rose by the limit on December 23.
Shenzhen Stock Exchange pointed out that on November 4, Aba Chemicals Corporation(300261) announced on the official website that “the commercialization and mass production of pharmaceutical intermediate carbonic anhydride developed and produced has been successful, and the monthly production scale has reached 20 tons at present”.
Recently, we have repeatedly responded to the business situation related to “carbonic anhydride” in interactive communication. Aba Chemicals Corporation(300261) in the interactive easy reply, it is mentioned that the company’s carbonic anhydride has achieved commercial production, but it will not have a significant impact on the company’s performance. On December 22, the company disclosed in the announcement on abnormal fluctuations in stock trading that the company did not directly supply carlon anhydride products to Pfizer. As of the announcement date, the sales revenue of carlon anhydride accounted for a relatively small proportion and would not have a significant impact on the company’s performance.
Shenzhen stock exchange requires Aba Chemicals Corporation(300261) to explain whether the company indirectly provides carlon anhydride products to Pfizer; In combination with the company’s product use, R & D and production investment, estimated production capacity, current production and sales volume, sales revenue and proportion, market share, orders in hand, main customers, position in relevant industrial chains, etc., explain the specific impact of the product on the company’s financial and operating conditions in the current and future periods, and fully prompt the risks.
In addition, Aba Chemicals Corporation(300261) also disclosed that the company’s Maltese subsidiary a2w Pharma Ltd. The main structure of CBD (cannabinoid) product production workshop has been basically completed and has not been officially put into operation. Shenzhen stock exchange requires it to supplement the specific situation of the company’s business involved in the field of industrial cannabis products, whether there is current production capacity and on-hand orders, etc.
At the same time, the company is required to explain whether the recent business situation and internal and external business environment have changed significantly, verify whether there are undisclosed information that should be disclosed, whether there are major events in planning or other market rumors and hot concepts that may have a great impact on the company’s stock trading price; Whether there is a situation of using information disclosure to cooperate with the reduction of holdings by the above personnel; Whether there is any violation of the principle of fairness of information disclosure or misleading investors, and whether there is any use of information disclosure to hype stock prices.
It is understood that Aba Chemicals Corporation(300261) is a customized manufacturer of pharmaceutical and pesticide fine chemicals. The company is committed to the research and development of high-end chemical technology. At present, the research results in the fields of chiral technology, nitrogen-containing heterocyclic derivatives and biological enzyme technology have reached the international advanced level. In addition, in the field of environmental protection industry, the company’s unique anaerobic digestion and industrial waste treatment technology is at the international leading level.
In the first three quarters of this year, the company achieved an operating revenue of 1.604 billion yuan, a year-on-year increase of 7.08%; The net profit attributable to the owners of the parent company was 151 million yuan, a year-on-year increase of 23.03%; The basic earnings per share was 0.1579 yuan, a year-on-year increase of 20.17%.
FDA Approves Pfizer covid-19 oral drug
China’s relevant cdmo industries are expected to benefit first
On December 22, FDA granted Pfizer the emergency use authorization (EUA) for the oral drug paxlovid of covid-19 for the treatment of mild to moderate covid-19 infection.
In this regard, Minsheng Securities said that Pfizer and MSD oral covid-19 drugs can effectively avoid the occurrence of severe covid-19. The two oral covid-19 drugs are suitable for high-risk groups with positive covid-19 test to help potential high-risk patients avoid severe covid-19. Meanwhile, China’s relevant cdmo industries are expected to take the lead in benefiting. Pfizer paxlovid expects to supply 180000 courses of treatment within the year and 80 million courses in 2022. The Chinese Cooperative suppliers are Porton Pharma Solutions Ltd(300363) , Asymchem Laboratories (Tianjin) Co.Ltd(002821) . Molnupiravir of MSD is expected to produce 10 million courses of treatment in the year and 20 million courses of treatment in 2022. The Chinese Cooperative suppliers are Zhejiang Tianyu Pharmaceutical Co.Ltd(300702) , Porton Pharma Solutions Ltd(300363) . The US government has ordered 10 million courses of Pfizer and 3 million courses of methadone, and the global order volume is expected to increase further.
Guosheng securities expects that the core business of pharmaceutical intermediates will usher in large-scale opportunities. Under the trend of continuous transfer of global cdmo to China, the share of China’s cdmo market in the world has increased from 4.6% to 9%, which is expected to reach 18% in 2025, which will continue to drive the growth of China Meheco Group Co.Ltd(600056) intermediate demand and promote its domestic substitution. Meanwhile, the core intermediate of covid-19 oral drug pf-07321332 is prepared by nitrogen heterocyclization of carbonic anhydride and reduction. Under the background that overseas production capacity has not fully recovered due to the impact of the epidemic, China’s cdmo and pharmaceutical intermediate industry chain is expected to fully benefit from the demand for covid-19 oral small molecule drugs. At present, the company has reached cooperation with Asymchem Laboratories (Tianjin) Co.Ltd(002821) to rapidly and stably supply intermediates required for the production of new drugs. At the same time, the company has reached a cooperation agreement with well-known pharmaceutical enterprises to provide them with important intermediates for new drugs for the treatment of heart failure.
Huachuang Securities said that with the improvement of vaccination rate and the smooth progress of covid-19 specific drugs, the impact of the epidemic has been gradually eliminated outside China, and the gradual liberalization of cross-border flows is the general trend for some time in the future. The aviation sector ushered in an investment opportunity period.
(China Fund News)
